Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer

HI Scher, D Lu, NA Schreiber, J Louw, RP Graf… - JAMA …, 2016 - jamanetwork.com
Importance A critical decision in the management of metastatic castration-resistant prostate
cancer (mCRPC) is when to administer an androgen receptor signaling (ARS) inhibitor or a …

Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms

H Tukachinsky, RW Madison, JH Chung… - Clinical Cancer …, 2021 - AACR
Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with
metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to …

Caspase-8 as a regulator of tumor cell motility

RP Graf, N Keller, S Barbero… - Current molecular …, 2014 - ingentaconnect.com
The caspases are a family of ubiquitously expressed cysteine proteases best known for their
roles in programmed cell death. However, caspases play a number of other roles in …

Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate …

HI Scher, RP Graf, NA Schreiber, A Jayaram… - JAMA …, 2018 - jamanetwork.com
Importance A blood test to determine whether to treat patients with metastatic castration-
resistant prostate cancer (mCRPC) with an androgen receptor signaling (ARS) inhibitor or …

Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer …

KA Autio, R Dreicer, J Anderson, JA Garcia… - JAMA …, 2018 - jamanetwork.com
Importance Preferential delivery of docetaxel to tumors by prostate-specific membrane
antigen (PSMA)–targeted nanoparticles is clinically effective, and the selective reduction of …

[HTML][HTML] Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer

HI Scher, RP Graf, NA Schreiber, B McLaughlin, D Lu… - European urology, 2017 - Elsevier
Abstract Background Circulating tumor cells (CTCs) expressing AR-V7 protein localized to
the nucleus (nuclear-specific) identify metastatic castration-resistant prostate cancer …

[HTML][HTML] Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

K Boudadi, DL Suzman, V Anagnostou, W Fu, B Luber… - Oncotarget, 2018 - ncbi.nlm.nih.gov
AR-V7-expressing metastatic prostate cancer is an aggressive phenotype with poor
progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests …

The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer

H Beltran, A Jendrisak, M Landers, JM Mosquera… - Clinical Cancer …, 2016 - AACR
Purpose: The transition of prostate adenocarcinoma to a predominantly androgen receptor
(AR) signaling independent phenotype can occur in the later stages of the disease and is …

Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer

HI Scher, RP Graf, NA Schreiber, B McLaughlin… - Cancer research, 2017 - AACR
The heterogeneity of an individual patient's tumor has been linked to treatment resistance,
but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical …

Analytical validation and capabilities of the epic CTC platform: enrichment-free circulating tumour cell detection and characterization

SL Werner, RP Graf, M Landers… - Journal of …, 2015 - journals.sagepub.com
The Epic Platform was developed for the unbiased detection and molecular characterization
of circulating tumour cells (CTCs). Here, we report assay performance data, including …